Mesna Baxter Healthcare (Mesna)

Mesna supplies sulfhydryl groups that bind to acrolein, the harmful by‑product of cyclophosphamide and ifosfamide metabolism. This binding creates a non‑toxic complex that is eliminated in the urine, thereby shielding the bladder lining from chemical injury.

The specific dose of Mesna is determined by the prescribing clinician based on the chemotherapy regimen, patient weight, renal function, and treatment schedule. Healthcare professionals tailor the amount to achieve optimal uroprotection while minimizing side effects.

Mesna is classified as pregnancy category D, indicating potential risk to the fetus. It should only be used when the therapeutic benefit justifies the risk. Limited data exist for breastfeeding; therefore, caution is advised and a healthcare provider should evaluate the situation.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Mesna is the most widely used thiol‑based uroprotective agent because it directly neutralises acrolein, the specific toxin responsible for chemotherapy‑induced cystitis. Alternative agents, such as sodium thiosulfate, target different toxic metabolites and are generally reserved for other chemotherapy agents. Mesna’s established safety profile and ease of administration make it the preferred choice for cyclophosphamide and ifosfamide regimens.

Mesna should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. For injectable solutions, avoid freezing and keep the vial sealed until use. Follow local pharmacy guidelines for handling sterile preparations.

Mesna can be given intravenously or taken orally, depending on the formulation supplied. It is typically administered shortly before, during, and after the chemotherapy infusion to ensure continuous protection of the bladder throughout the treatment cycle.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, hemolytic anemia (especially in patients with G6PD deficiency), and pulmonary edema. Prompt medical attention is required if any of these symptoms develop.

Mesna is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is also advised for individuals with severe renal impairment, G6PD deficiency, or those who are pregnant unless the potential benefit outweighs the risk.